Efficacy and safety of sildenafil in hypertensive patients with erectile dysfunction
Abstract
Erectile dysfunction (ED) is common among hypertensive men, associated to hypertension itself and/or as a consequence of antihypertensive treatment. Accordingly, we evaluated the efficacy and safety of Sildenafil (PDE5 inhibitor) administered to hypertensive men with ED. We studied 52 >18-year men with previously-diagnosed essential hypertension, 57.1 ± 9.5 years of age, with blood pressure (BP) below 160/100 mm Hg, and with diagnosis of ED determined by the Sexual Health Inventory for Men (SHIM) and the International Index of Erectile Function (IIEF). ED is defined as a punctuation below 21/26 for SHIM/IIEF. 30 patients were receiving monotherapy and the other 22 a combined therapy with up to 3 drugs. After diagnosis of ED, Sildenafil was prescribed to be administered 60 min before sexual intercourse, at an initial dose of 50 mg, increased up to 100 mg in absence of response. Efficacy was evaluated by application of new SHIM and IIEF questionnaires after treatment. Safety was evaluated by analysis of adverse events reported by the patients. Fourteen patients (26.9%) had severe ED, 18 (34.6%) had moderate ED, and the remaining 20 (38.5%) presented mild ED. The lower dose of 50 mg of Sildenafil was used by 32 patients (61.5%). Changes in BP, heart rate (HR), and SHIM and IIEF scores were as follows: Only 14 patients (26.9) presented mild transient adverse effects. The reported adverse effects were headache (13.5%), blushing (9.6%), dyspepsia (5.8%), dizziness (3.8%), visual…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.